BioSpace: ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration

“ShangPharma Innovation Inc., a global venture capital firm focused on biomedical R&D therapeutics and technologies, and Icahn School of Medicine at Mount Sinai (ISMMS) have entered into a multi-year strategic collaboration to accelerate the development of novel early-stage therapeutics.

Under the terms of the agreement, ShangPharma Innovation will provide funding and preclinical research support to further ISMMS’s objectives of validating drug targets and establishing programs to discover new therapies. ShangPharma and Mount Sinai will share in the future value created through the collaboration.”

Media Inquiries

Heidi Chokeir, Ph.D.
Canale Communications
[email protected]